scholarly journals Inclusion of the other in the self as a potential risk factor for prolonged grief disorder: A comparison of patients with matched bereaved healthy controls

Author(s):  
Octavia Harrison ◽  
Sabine Windmann ◽  
Rita Rosner ◽  
Regina Steil
2021 ◽  
Author(s):  
Octavia Harrison ◽  
Sabine Windmann ◽  
Rita Rosner ◽  
Regina Steil

Pathological grief has received increasing attention in recent years, as about A10% of the bereaved suffer from one kind it. Pathological grief in the form of Prolonged grief disorder (PGD) is a relatively new diagnostic category which has been introduced into the ICD-11 beta version in 2018. To date, various risk and protective factors, as well as treatment options for pathological grief, have been proposed. Nevertheless, empirical evidence in that area is still scarce. Our aim was to identify the impact interpersonal closeness with the deceased has on bereavement outcome.Interpersonal closeness with the deceased in 54 participants (27 patients suffering from PGD and 27 bereaved healthy controls) was assessed as the overlap of pictured identities via the Inclusion of the Other in the Self Scale (IOS-scale). In addition to that, data on PGD symptomatology, general mental distress, and depression were collected.Patients suffering from PGD reported higher inclusion of the deceased in the self. By contrast, they reported feeling less close towards another living close person. Results of the IOS-scale were associated with PGD-severity, general mental distress, and depression. Inclusion of the deceased in the self is a significant statistical predictor for PGD-caseness.


2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Samuel Bitoun ◽  
Julien Henry ◽  
Christelle Vauloup-Fellous ◽  
Nicolas Dib ◽  
Rakiba Belkhir ◽  
...  

AbstractPatients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to examine response to mRNA vaccine between healthy controls (n = 28) and multiple myeloma (MM) patients (n = 27). Response was analyzed 1 month after the second dose of anti-SARS-CoV-2 BNT162b2 vaccine. Multiple myeloma patients showed diminished levels of Anti-Spike IgG levels compared to controls, but with a high proportion of patients achieving a humoral response (89% vs. 97% in controls). Neutralizing antibodies were present in 74% of patients versus 96% of controls. Patients under current daratumumab treatment had neutralizing activity of anti-SARS-CoV-2 antibodies. Multiple myeloma patients show diminished response to SARS-COV-2 vaccine but with still high response rate. The main potential risk factor of non-response to COVID-19 vaccine was uncontrolled disease under treatment.


2005 ◽  
Vol 40 (1) ◽  
pp. 87-95 ◽  
Author(s):  
Yong-Hee P. Chun ◽  
Kyoung-Ryul J. Chun ◽  
De'Avlin Olguin ◽  
Hom-Lay Wang

PLoS ONE ◽  
2019 ◽  
Vol 14 (4) ◽  
pp. e0214840 ◽  
Author(s):  
Mais Ali-Saleh ◽  
Ofer Lavie ◽  
Yoram Abramov

Surgery Today ◽  
2013 ◽  
Vol 44 (6) ◽  
pp. 1084-1089 ◽  
Author(s):  
Yoichiro Homma ◽  
Takashi Hamano ◽  
Yasuhiro Akazawa ◽  
Yoshiro Otsuki ◽  
Shinichi Shimizu ◽  
...  

2017 ◽  
Vol 27 (8) ◽  
pp. 716-721
Author(s):  
Arvind Tripathi ◽  
Soumyojeet Bagchi ◽  
Juhi Singh ◽  
Paritosh Pandey ◽  
Suryakant Tripathi ◽  
...  

2018 ◽  
Vol 111 (2) ◽  
pp. 62-69 ◽  
Author(s):  
Romy van de Putte ◽  
Ivo de Blaauw ◽  
Rianne Boenink ◽  
Monique H.E. Reijers ◽  
Paul M.A. Broens ◽  
...  

Author(s):  
Elodie Gautier‐Veyret ◽  
Aurélie Truffot ◽  
Sébastien Bailly ◽  
Xavier Fonrose ◽  
Anne Thiebaut‐Bertrand ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document